Medication-Assisted Treatment. What Is It and Why Do We Use It?

Similar documents
MEDICATION ASSISTED TREATMENT

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

The CARA & Buprenorphine Prescribing for APNs & PAs

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

Closing the Loop in Treating Opioid Addiction:

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Treatment Approaches for Drug Addiction

Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Treatment Alternatives for Substance Use Disorders

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Medication Assisted Treatment as an alternative in Drug Courts*

AGENDA U.S. SURGEON GENERAL, VIVEK MURTHY MD 2/5/2019

U.S. SURGEON GENERAL, VIVEK MURTHY MD

Medication-Assisted Treatment (MAT) Overview

2/21/2018. What are Opioids?

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Medication Assisted Treatment:

Medication Assisted Treatment

Understanding Medication in Addiction Treatment for Drug Court Participants

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

SUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS

Building capacity for a CHC response to Ontario's Opioid Crisis

Buprenorphine as a Treatment Option for Opioid Use Disorder

Restoration of Parenting Ability Through Treatment for Substance Use Disorders

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Medication-Assisted Treatment (MAT) for Opioid Use Disorders

MAT in the Corrections Setting

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Supporting Sustained Recovery for Opioid Use Disorder

HARM REDUCTION & TREATMENT. Devin Reaves MSW

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Vivitrol Vs. Suboxone

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

Medicaid and the Opioid Crisis

Addressing Opiate Abuse

Opioid Dependence and Buprenorphine Management

THE STATE OF MEDICINE IN ADDICTION RECOVERY

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction

Corporate Medical Policy

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Appendix F Federation of State Medical Boards

Naltrexone protocol alcohol

MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER

Helping Recovery Residences Adapt

How serious is the opiate problem in Fairfield County?

Vivitrol Drug Court and Medication Assisted Treatment

THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Opioids Research to Practice

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Anyone Can Become Addicted. Anyone.

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

Treatment of Opioid Use Disorder

Treatment of Opioid Use Disorder

Opiate Use Disorder and Opiate Overdose

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

Serious Mental Illness and Opioid Use Disorder

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

The following presentation may not be copied in whole or in part without the written permission of the author Celeste

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford

Buprenorphine addiction

Medication for Addiction Treatment (MAT)

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

Medication Assisted Treatment. Michael Palladini, RPh MBA CAC

Methadone and Naltrexone ER

GOALS AND OBJECTIVES

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder

Methadone Maintenance 101

Management Options for Opioid Dependence:

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

Pregnancy, MAT and Addiction

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet

MEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use

Opioids Research to Practice

Ken Roy, MD, FASAM. The Opioid Epidemic and Addiction Involving the Use of Opioids. Tulane & LSU Department of Psychiatry

Overview of Opioid Use Disorder

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

Today s workshop is sponsored by BSAS

Prescription Opioid Addiction

Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant

The Social Worker s Role in Medication Assisted Treatment

Aetna s Initiative on the Opioid Epidemic

DISCLOSURES MANAGEMENT OF OPIOID USE DISORDERS LECTURE COVERS. SUDs ARE IMPORTANT. I have nothing to declare

Transcription:

Medication-Assisted Treatment What Is It and Why Do We Use It?

What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite Consequences. Addiction is defined as a chronic, relapsing brain disease that is characterized by compulsive drug seeking and use, despite harmful consequences. It is considered a brain disease because drugs change the brain they change its structure and how it works. These brain changes can be long-lasting, and can lead to the harmful behaviors seen in people who abuse drugs.

Cocaine Abuse and Brain Glucose Metabolism normal subject cocaine abuser (10 days post) cocaine abuser (100 days post)

Effect of Cocaine Abuse on Dopamine D2 Receptors normal subject cocaine abuser (1 month post) cocaine abuser (4 months post)

Treating Substance-Use Disorders Addiction IS a treatable disease. Treatment MUST address the whole person and must be multifaceted. Simply stopping the use of substances does not equate to recovery. MAT is an extremely valuable tool in the treatment of addiction and produces better, long-term outcomes for individuals, families, and communities.

Treating Substance-Use Disorders Harm reduction / abstinence. Behavioral therapies. Self help / Support groups. Stable support system. Finding meaning/purpose in life. Addressing co-occurring mental health issues and other psychosocial stressors. Addressing physical health concerns. Medication-Assisted Treatment. And more

What is Medication-Assisted Treatment? The use of medication to assist in the treatment of various aspects of the addiction process. It is only one tool in the tool box of treatment & recovery. MAT uses FDA approved medications for several different substance-use disorders, notably alcohol and opiates.

What is Medication-Assisted Treatment? MAT can be used to help withdraw people from addictive drugs. MAT can be used to help prevent people from returning to specific drug use (relapse). Decreasing cravings for the drug. Blocking reinforcing effect of the drug when used.

MAT for Alcohol For alcohol withdrawal: Benzodiazepines to ease symptoms and prevent delirium tremens (DTs). Valium, Librium, Ativan For relapse prevention: Disulfuram Acamprosate Naltrexone

Why use MAT for alcohol? For alcohol withdrawal: Decreased morbidity and mortality. Increased odds person will progress to treatment. Increased therapeutic rapport and thus compliance. For alcohol relapse prevention: Increased time to first drink. Decreased number of drinks per drinking episode. Increased time to full relapse.

MAT for Opiates For opiate withdrawal: Clonidine (ok, NOT FDA approved) Methadone Buprenorphine For relapse prevention: Methadone Buprenorphine Naltrexone

Why Use MAT for opiates? For opiate withdrawal Decreased morbidity and mortality. Increased number of people completing Detox. (methadone>buprenorphine>clonidine> cold turkey ) For relapse prevention: Decrease in return to illicit/uncontrolled opiate use. How can you relapse if you never stopped using opiates?

The Case for Using Opiates to Treat Opiate Use disorder Standard treatments have poor outcomes for many with opiate use disorder. Harm reduction approach for the individual. Public Health issue for society. Public Safety. When used to treat opioid addiction, MAT stabilizes brain chemistry, blocks the euphoric effects of opioids (the high ), relieves physiological cravings, and normalizes body functions. Numerous studies have shown that MAT reduces illicit drug use, disease rates, overdose, mortality, and criminal behavior. The use of MAT allows time for the person to develop the skills needed to become sober before expecting them to be able to maintain abstinence.

Some Important Numbers: 42,249 opiate overdose deaths in 2016. 2.1 million people with opiate use disorders in 2016. 40-60% of people with alcohol and MOST drug use disorders remained abstinent one year after treatment.

Medication Assisted Treatment Can employ both potentially addicting as well as non-addictive medications. Can be used to help with various phases of the addiction cycle. Can be useful for substance-use disorders which are exceptionally difficult to treat. Cannot serve as a substitute for other modalities of treatment. Cannot be used as stand alone treatment (medications).

MAT and the Criminal Justice System Many justice-involved individuals need treatment for opioid and alcohol dependence. It is estimated that up to 45% of people who are incarcerated have both substance use and mental disorders. We know from multiple studies that addiction treatment programs, especially when combined with MAT, reduce recidivism and re-incarceration. One study found that every $1 spent on treatment saved $5.60 in terms of fewer arrests and incarceration costs. Specialty courts are having a major impact: Nationwide, 75% of Drug Court graduates remain arrest-free at least two years after leaving the program. Rigorous studies examining long-term outcomes of individual Drug Courts have found that reductions in crime lasts at least 3 years.

Methadone Methadone is the most widely used medication for this purpose in the world (it has been in use a long time). Methadone both reduces cravings for illicit opioids and prevents withdrawal symptoms. Methadone must be dispensed by opioid treatment programs (OTPs) that are regulated at federal and state levels. Has limited side effects and contraindications. Methadone is sometimes preferred for individuals who have been abusing high doses of opioids for long periods of time.

Buprenorphine Approved for clinical use in October 2002 by the Food and Drug Administration (FDA), buprenorphine represents the latest advance in medication-assisted treatment. Reduces cravings for and withdrawal symptoms from opioids. Has limited side effects and contraindications. Has less abuse potential than methadone and is less likely to result in medically significant harm if misused.

Buprenorphine Unlike Methadone, Buprenorphine can be prescribed by outpatient providers who have completed special training and have obtained their DATA 2000 waiver. Buprenorphine/Naloxone combination: Naloxone is an antagonist. It is added to block any euphoric effects of buprenorphine that would occur if a person were to abuse the medication by injecting it, thus decreasing the desirability of the medication for abuse/misuse. Bunavail (buprenorphine and naloxone) buccal film Suboxone (buprenorphine and naloxone) film Zubsolv (buprenorphine and naloxone) sublingual tablets Cassipa (buprenorphine and naloxone) Brand new product, film, higher dose

Buprenorphine Ideal Candidates for Buprenorphine: Have been objectively diagnosed with an opioid dependency. Are willing to follow safety precautions for the treatment. Have been cleared of any health conflicts with using buprenorphine. Have reviewed other treatment options before agreeing to buprenorphine treatment. Have a reasonable level of stability and support. Are willing to engage in other behaviorally-based therapies.

Buprenorphine The Induction Phase : Medically monitored by a qualified physician s office or certified OTP using approved buprenorphine products. Buprenorphine can bring on acute withdrawal for patients who are not in the early stages of withdrawal and who have other opioids in their bloodstream; patients should have a minimum of 12-24 hours from their last use. The Stabilization Phase: Patient has discontinued or greatly reduced their misuse of the problem drug, no longer has cravings, and experiences few, if any, side effects. The buprenorphine dose may need to be adjusted during this phase. The Maintenance Phase: Patient is doing well on a steady dose of buprenorphine. The length of time of the maintenance phase is tailored to each patient and could be indefinite. Titration and Discontinuation Phase: Once an individual is stabilized and it is clinically appropriate, they can begin a medically supervised titration and discontinuation. Patients are encouraged to continue rehabilitation with or without MAT to prevent a possible relapse.

Naltrexone Naltrexone is used for both alcohol and opiate dependence. Naltrexone is an opioid antagonist; it fully blocks the effects of opioids such as heroin and oxycodone. There is a risk of overdose when opioids are used while on Naltrexone. It can be given in pill form, or as an extended release injection (Vivitrol) that last approximately 28 days.

Naltrexone Naltrexone is not a controlled substance and has no abuse or diversion potential, offering an alternative to methadone or buprenorphine as well as expanding access to MAT. Naltrexone is ideal for individuals who have already detoxed from alcohol and/or opioids or have high level of motivation to remain clean and sober. Naltrexone (Vivtrol) can be utilized for individuals exiting incarceration or treatment programs to help prevent relapse.

Does MAT substitute one drug for another? NO. Though two of the three MAT medications (methadone and buprenorphine) are opioid-based, they are fundamentally different from short-acting opioids such as heroin and prescription painkillers. Short-acting opioids travel directly to the brain and narcotize the individual, causing sedation and the euphoria known as a high. In contrast, methadone and buprenorphine, when properly prescribed and utilized, reduce drug cravings and prevent relapse without causing a high. Naltrexone is not opioid based and does not result in physical dependence. MAT medications help patients disengage from drug seeking and related criminal behavior and become more receptive to behavioral treatments.

How do we identify the MAT appropriate patient? Assessing for readiness: Screening tools Determining level of care: ASAM evaluation Clinical determination based on 6 biopsychosocial dimensions. Voluntary vs. mandated patients.

Screening Tools PMQ: Pain Medication Questionnaire COMM: Current Opioid Misuse Measure PDUQ: Prescription Drug Use Questionnaire CAGE-AID: Cut Down, Annoyed, Guilty, Eye-Opener tool, adjusted to include drugs RAFFT: Relax, Alone, Friends, Family, Trouble DAST: Drug Abuse Screening Test SBIRT: Screening, Brief Intervention & Referral to Treatment ASAM Criteria: American Society of Addiction Medicine COWS: Clinical Opiate Withdrawal Scale

Naloxone (Narcan) Naloxone is a medication that can be used to treat an opioid overdose in an emergency situation.

In Summary Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to provide a whole-patient approach to treatment of substance use disorders. MAT is primarily used for the treatment of addiction to opioids such as heroin and prescription pain relievers, as well as, alcohol. The prescribed medication operates to normalize brain chemistry, block the euphoric effects of alcohol and opioids, relieve physiological cravings, and normalize body functions without the negative effects of the abused drug.

In Summary MAT is not replacing one addiction for another. It is a safe, effective, medically-monitored, evidenced-based treatment for a the neurobiological disease of addiction. MAT improves outcomes for individuals, families, and communities. Naloxone is a life-saving medication that continues to be dispersed throughout our state.

Questions, Comments, Concerns, Complaints?